CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
(SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon...
Phase 3
New York, New York, United States and 250 other locations
with histologically or cytologically confirmed stage IV colorectal cancer coming form three different patient populations:* Cohort 1a: 6 pat...
Phase 1
New York, New York, United States and 11 other locations
(PK) of BBO-8520, a KRAS G12C (ON) inhibitor, single agent and in combination with pembrolizumab in patients with advanced non-small cell lung cancer...
Phase 1
Norwalk, Connecticut, United States and 14 other locations
and pembrolizumab) given together for the treatment of colorectal cancer that:* is metastatic (spread to other parts of the body);* has the ...
Phase 2
New York, New York, United States and 111 other locations
dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors, including but not limited to cholangiocarcinoma, chondrosarcoma, an...
Phase 1
New York, New York, United States and 32 other locations
is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors...
Phase 1
New York, New York, United States and 16 other locations
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor ...
Phase 1, Phase 2
New York, New York, United States and 83 other locations
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors....
Phase 1
New York, New York, United States and 15 other locations
the efficacy of CTX-009 in patients with metastatic colorectal cancer.A Simon Two-Stage adaptive design will enroll approximately 37 patient...
Phase 2
New Brunswick, New Jersey, United States and 6 other locations
This study is to evaluate the safety, tolerability, and PK profiles of RMC-6291 and RMC-6236 in adults with KRAS G12C-mutated solid tumors....
Phase 1
New York, New York, United States and 27 other locations
Clinical trials
Research sites
Resources
Legal